Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pieris Pharmaceuticals Inc PIRS

Healthcare Biotechnology
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.


NDAQ:PIRS - Post by User

Pieris Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Post by AviseAnalyticson Oct 11, 2021 7:46am
169 Views
Post# 33994616

PIERIS’S ANTICALIN COULD BE A GAMECHANGER!

PIERIS’S ANTICALIN COULD BE A GAMECHANGER! $PIRS

Pieris Pharmaceuticals, (NASDAQ: PIRS) is a clinical-stage biopharmaceutical company that is leveraging its proprietary Anticalin® technology for creating novel therapeutics for the treatment of immuno-oncology and respiratory diseases. 

A highly differentiated technology, multiple strategic partnerships and upcoming readouts from a crucial Phase 2a trial of PRS-060/AZD1402, an inhaled IL-4 receptor alpha inhibitor, intended for the treatment of moderate-to-severe asthma in collaboration with AstraZeneca, make this Company a must watch!

Learn more

https://www.aviseanalytics.com/pieriss-anticalin-could-be-a-gamechanger/


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities